Fractyl Health (NASDAQ:GUTS) CFO Buys $13,800.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CFO Weber Lara Smith bought 20,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was bought at an average cost of $0.69 per share, with a total value of $13,800.00. Following the transaction, the chief financial officer directly owned 20,000 shares of the company’s stock, valued at approximately $13,800. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $0.72 on Friday. Fractyl Health, Inc. has a 1-year low of $0.38 and a 1-year high of $2.45. The business has a 50-day moving average of $0.69 and a 200-day moving average of $1.07. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company has a market capitalization of $114.85 million, a price-to-earnings ratio of -0.56 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. On average, equities analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. FNY Investment Advisers LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $31,000. Jane Street Group LLC acquired a new stake in Fractyl Health during the second quarter valued at approximately $31,000. Accredited Investors Inc. acquired a new stake in Fractyl Health during the first quarter valued at approximately $46,000. Scientech Research LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $49,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $55,000.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GUTS. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.